TAS-119

DRUG2 trials

Sponsors

Taiho Oncology, Inc.

Conditions

Advanced Solid Tumors

Phase 1

Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors

TerminatedNCT02134067

Taiho Oncology, Inc.Advanced Solid Tumors

Start: 2014-08-31End: 2018-07-31Updated: 2024-09-05

An Investigation of TAS-119 Monotherapy

TerminatedNCT02448589

Taiho Oncology, Inc.Advanced Solid Tumors

Start: 2014-09-30End: 2019-08-31Updated: 2024-09-04

Related Papers

A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours.

2020-10-0615 citations

Phase I study of the Aurora A kinase (AurA) inhibitor TAS-119 with paclitaxel (P) in advanced solid tumors.

Journal of Clinical Oncology2019-05-203 citations

First-in-human phase I and pharmacological study of TAS-119, a selective Aurora A (AurA) kinase inhibitor, in patients (pts) with advanced solid tumors.

Journal of Clinical Oncology2019-05-203 citations